Modulation of Protein-Protein Interactions for the Development of Novel Therapeutics

被引:140
|
作者
Petta, Ioanna [1 ,2 ,3 ,4 ]
Lievens, Sam [1 ,2 ]
Libert, Claude [3 ,4 ]
Tavernier, Jan [1 ,2 ]
De Bosscher, Karolien [1 ,2 ,5 ]
机构
[1] VIB, Receptor Res Labs, CRL, Dept Med Prot Res, Albert Baertsoenkaai 3, B-9000 Ghent, Belgium
[2] Univ Ghent, Dept Biochem, B-9000 Ghent, Belgium
[3] VIB, Inflammat Res Ctr, B-9000 Ghent, Belgium
[4] Univ Ghent, Dept Biomed Mol Biol, B-9000 Ghent, Belgium
[5] VIB, Receptor Res Labs, NRL, Dept Med Prot Res, B-9000 Ghent, Belgium
关键词
SMALL-MOLECULE INHIBITORS; SITE INTEGRASE INHIBITOR; ESTROGEN-RECEPTOR-ALPHA; BCL-2 FAMILY PROTEINS; MENIN-MLL INTERACTION; AMYLOID-BETA PEPTIDE; P53; PATHWAY; NEURODEGENERATIVE DISEASES; CLINICAL DEVELOPMENT; MCL-1; INHIBITORS;
D O I
10.1038/mt.2015.214
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Protein-protein interactions (PPIs) underlie most biological processes. An increasing interest to investigate the unexplored potential of PPIs in drug discovery is driven by the need to find novel therapeutic targets for a whole range of diseases with a high unmet medical need. To date, PPI inhibition with small molecules is the mechanism that has most often been explored, resulting in significant progress towards drug development. However, also PPI stabilization is gradually gaining ground. In this review, we provide a focused overview of a number of PPIs that control critical regulatory pathways and constitute targets for the design of novel therapeutics. We discuss PPI-modulating small molecules that are already pursued in clinical trials. In addition, we review a number of PPIs that are still under preclinical investigation but for which preliminary data support their use as therapeutic targets.
引用
收藏
页码:707 / 718
页数:12
相关论文
共 50 条